Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer
文献类型：期刊论文
| 作者 | Zhai, Guijin1,4; Yang, Liping2; Luo, Qun1,3; Wu, Kui1; Zhao, Yao1; Liu, Jianan1; Xiong, Shaoxiang1; Wang, Fuyi1,3 |
| 刊名 | RSC ADVANCES
 |
| 出版日期 | 2017 |
| 卷号 | 7期号:35页码:21630-21637 |
| ISSN号 | 2046-2069 |
| DOI | 10.1039/c7ra00827a |
| 英文摘要 | Gastric cancer (GC) is the fourth most commonly diagnosed cancer and the third leading cause of cancer-related deaths. Most GC deaths can be prevented by early diagnosis. However, biomarkers with high sensitivity and specificity are rare. Comprehensive serum phosphopeptides analysis may lead to the discovery of novel biomarkers for GC. In this work, we report a mass spectrometric strategy for the evaluation of serum phosphopeptides separated and enriched by ZrAs-Fe3O4@SiO2 nanoparticles. Four endogenous phosphopeptides in sera generated by degradation of fibrinogen were synthesized with light- and heavy-glycine residues, respectively, as external/internal standards, and used to gain multi-point standard calibration curves for absolute quantification of phosphopeptides by LC-ESI-MS following ZrAs-Fe3O4@SiO2 enrichment. The ESI-MS signal ratios of the four pairs of light-/heavy-phosphopeptide standards captured by ZrAs-Fe3O4@SiO2 from aqueous solutions are linearly correlated with the molar ratios of the "light" to "heavy" phosphopeptides over the range of 0.05-5 mu M with an r(2) of up to 0.998 and a slope of close to 1. The recovery of the four phosphopeptides spiked at low, medium and high levels in human sera were 94.7-107.5% with RSDs in the range of 0.6-8.2%. The validated method was utilized to measure the phosphopeptide levels of serum samples from 30 healthy persons and 60 GC patients. Receiver operating characteristic (ROC) analysis shows that one phosphopeptide (F3: DpSGEGDFLAEGGGVR) yields high sensitivity and specificity of 90.0% and 96.7%, respectively, in the validation set for discriminating GC patients from healthy controls. Overall, 53 of 60 GC cases and 29 of 30 controls were correctly classified, including eight of nine GC patients at stage I. These results suggest that F3 in sera may be a potential biomarker for GC diagnosis, particularly for early stage cases. |
| 语种 | 英语 |
| WOS记录号 | WOS:000399810800034 |
| 出版者 | ROYAL SOC CHEMISTRY |
| 源URL | [http://ir.iccas.ac.cn/handle/121111/44949]  |
| 专题 | 中国科学院化学研究所 |
| 通讯作者 | Wang, Fuyi |
| 作者单位 | 1.Chinese Acad Sci, CAS Res Educ Ctr Excellence Mol Sci, Beijing Natl Lab Mol Sci,Natl Ctr Mass Spectromet, CAS Key Lab Analyt Chem Living Biosyst,Inst Chem, Beijing 100190, Peoples R China 2.Nantong Univ, Tumour Hosp, Canc Res Ctr, Nantong 226361, Jiangsu, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China 4.Tianjin Med Univ, Tianjin Key Lab Med Epigenet, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhai, Guijin,Yang, Liping,Luo, Qun,et al. Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer[J]. RSC ADVANCES,2017,7(35):21630-21637. |
| APA | Zhai, Guijin.,Yang, Liping.,Luo, Qun.,Wu, Kui.,Zhao, Yao.,...&Wang, Fuyi.(2017).Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer.RSC ADVANCES,7(35),21630-21637. |
| MLA | Zhai, Guijin,et al."Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer".RSC ADVANCES 7.35(2017):21630-21637. |
入库方式： OAI收割
来源：化学研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。